Cargando…

The synergetic effect of sitafloxacin–arbekacin combination in the Mycobacterium abscessus species

Mycobacterium abscessus species (MABS) is the most commonly isolated rapidly growing mycobacteria (RGM) and is one of the most antibiotic-resistant RGM with rapid progression, therefore, treatment of MABS is still challenging. We here presented a new combination treatment with sitafloxacin that targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Junko, Ihara, Hiroaki, Takei, Satomi, Nakamura, Ayako, Fujimoto, Yuichi, Handoh, Tetsuya, Kurokawa, Kana, Arai, Yuta, Shibayama, Kohei, Sumiyoshi, Issei, Ochi, Yusuke, Okabe, Takahiro, Misawa, Shigeki, Togo, Shinsaku, Naito, Toshio, Tabe, Yoko, Miida, Takashi, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899205/ https://www.ncbi.nlm.nih.gov/pubmed/36739345 http://dx.doi.org/10.1038/s41598-023-29021-0

Ejemplares similares

The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex
por: Takei, Satomi, et al.
Publicado: (2020)

Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity
por: He, Siyuan, et al.
Publicado: (2022)

Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy
por: Okabe, Takahiro, et al.
Publicado: (2020)

Clinical Usefulness of Arbekacin
por: Lee, Jae Hoon, et al.
Publicado: (2016)

The usefulness of arbekacin compared to vancomycin
por: Hwang, J.-H., et al.
Publicado: (2011)

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting
por: Kato, Motoyasu, et al.
Publicado: (2021)

High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
por: Sumiyoshi, Issei, et al.
Publicado: (2021)

Severe Pulmonary Mycobacterium abscessus Cases Due to Co-Infection with Other Microorganisms Well Treated by Clarithromycin and Sitafloxacin in Japan
por: Takano, Kazuki, et al.
Publicado: (2021)

Arbekacin as an Alternative Drug to Teicoplanin for the Treatment of MRSA Infection
por: Hwang, Ji-Hee, et al.
Publicado: (2016)

Mechanistic insights into translation inhibition by aminoglycoside antibiotic arbekacin
por: Parajuli, Narayan Prasad, et al.
Publicado: (2021)

Novel conditionally replicating adenovirus-mediated efficient detection of circulating tumor cells in lung cancer patients
por: Ikemoto, Sena, et al.
Publicado: (2023)

Spread of Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates Producing NDM-Type Metallo-β-Lactamase in Myanmar
por: Takei, Satomi, et al.
Publicado: (2022)

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus
por: Lee, Ji-Young, et al.
Publicado: (2006)

Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment
por: Takei, Satomi, et al.
Publicado: (2022)

Comparative In Vitro Activity of Ciprofloxacin and Sitafloxacin Against Neisseria gonorrheae
por: Thamlikitkul, Visanu, et al.
Publicado: (2017)

The Efficacy and Safety of Arbekacin and Vancomycin for the Treatment in Skin and Soft Tissue MRSA Infection: Preliminary Study
por: Hwang, Ji-Hee, et al.
Publicado: (2013)

Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus
por: Hwang, Ji-Hee, et al.
Publicado: (2015)

CT Guided Needle Biopsy of Peripheral Lesions–Lesion Characteristics That May Increase the Diagnostic Yield and Reduce the Complication Rate
por: Tajima, Manabu, et al.
Publicado: (2021)

Investigation of the individual genetic evolution of SARS-CoV-2 in a small cluster during the rapid spread of the BF.5 lineage in Tokyo, Japan
por: Jin, Bo, et al.
Publicado: (2023)

Doxycycline and Sitafloxacin Combination Therapy for Treating Highly Resistant Mycoplasma genitalium
por: Durukan, Duygu, et al.
Publicado: (2020)

Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase
por: Iwashita, Yoshiaki, et al.
Publicado: (2013)

Complete Genome Sequence of a Type Strain of Mycobacterium abscessus subsp. bolletii, a Member of the Mycobacterium abscessus Complex
por: Yoshida, Mitsunori, et al.
Publicado: (2018)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections
por: Tanigawara, Yusuke, et al.
Publicado: (2013)

Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis
por: Manosuthi, Weerawat, et al.
Publicado: (2016)

Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
por: Asakura, Takanori, et al.
Publicado: (2019)

1423. Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients With Pneumonia
por: Paiboonvong, Taniya, et al.
Publicado: (2018)

Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy
por: Sue, Soichiro, et al.
Publicado: (2021)

Clinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies
por: Ohashi, Takashi, et al.
Publicado: (2022)

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2019)

Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2020)

Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
por: Takahashi, Maika, et al.
Publicado: (2023)

Synergetics
por: Hutt, Axel, et al.
Publicado: (2020)

Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii
por: Xu, Nannan, et al.
Publicado: (2018)

Efficacy and Safety of Sitafloxacin in Treating Low-risk Febrile Neutropenia in Patients with Lung Cancer
por: On, Rintaro, et al.
Publicado: (2022)

Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report
por: Kurokawa, Kana, et al.
Publicado: (2020)

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
por: Matsumoto, Tetsuya
Publicado: (2014)

Complexity and synergetics
por: Müller, Stefan C, et al.
Publicado: (2017)

Foundations of synergetics
por: Mikhailov, Alexander S
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_o2jqbe6qmsn92glvkq2tfitj6a